(Q44263320)

1 December 2017

PENTA guidelines for the use of antiretroviral therapy, 2004. (English)

1 reference

1 December 2017

anti-retroviral agent

0 references

5

D M Gibb

1 reference

1 December 2017

M Sharland

1

1 reference

1 December 2017

S Blanche

2

1 reference

1 December 2017

G Castelli

3

1 reference

1 December 2017

J Ramos

4

1 reference

1 December 2017

PENTA Steering Committee

6

1 reference

1 December 2017

language of work or name

1 reference

1 July 2004

1 reference

1 December 2017

1 reference

1 December 2017

5 Suppl 2

1 reference

1 December 2017

61-86

1 reference

Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis.

1 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Nevirapine use in HIV-1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Tolerance of efavirenz in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Phase I/II trial of intravenous recombinant interleukin-2 in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Adherence to medication regimens among children with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Assessment of adherence with medications in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Gastrostomy tube placement in nonadherent HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a strategy for antiretroviral management in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Metabolic complications of antiretroviral therapy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Lipodystrophy syndrome in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

High prevalence of osteonecrosis of the femoral head in HIV-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

HIV infection--a risk factor for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Bone mineral content is lower in prepubertal HIV-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

Combination Nucleoside Analog Reverse Transcriptase Inhibitor(s) Plus Nevirapine, Nelfinavir, or Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children: Week 24 Results of a Randomized Controlled Trial - PACTG 377

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00227.X

10.1111/J.1468-1293.2004.00227.X

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference